Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics

Author(s): P. Msaouel, I. D. Iankov, A. Dispenzieri, E. Galanis

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 9 , 2012


Become EABM
Become Reviewer
Call for Editor

Abstract:

Attenuated measles virus vaccine strains have emerged as a promising oncolytic vector platform, having shown significant anti-tumor activity against a broad range of malignant neoplasms. Measles virus strains derived from the attenuated Edmonston-B (MV-Edm) vaccine lineage have been shown to selectively infect, replicate in and lyse cancer cells while causing minimal cytopathic effect on normal tissues. This review summarizes the preclinical data that led to the rapid clinical translation of oncolytic measles vaccine strains and provides an overview of early clinical data using this oncolytic platform. Furthermore, novel approaches currently under development to further enhance the oncolytic efficacy of MV-Edm strains, including strategies to circumvent immunity or modulate immune system responses, combinatorial approaches with standard treatment modalities, virus retargeting as well as strategies for in vivo monitoring of viral replication are discussed.

Keywords: Cancer gene therapy, cell carriers, combination therapy, oncolytic measles, tumor targeting, virotherapy, measles, attenuatedEdmonston-B (MV-Edm), oncolytic efficacy

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 9
Year: 2012
Published on: 14 June, 2012
Page: [1732 - 1741]
Pages: 10
DOI: 10.2174/138920112800958896
Price: $65

Article Metrics

PDF: 5